Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Novo Nordisk (NVO), which develops weight-loss drugs, looks poised to perform well over the short term, Rebecca Walser, the ...

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...

I n an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top executives met, like they had dozens of times before, to hear the ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

European equities are heading for a sharply higher open, with investors still reeling from one of the wildest weeks for ...

In the sleepy suburb of Bagsværd, a 25-minute train ride from Denmark’s capital of Copenhagen, weight-loss drugmaker Novo Nordisk is everywhere. Street after street is filled with the company ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes ...

It has been a tough period for Novo Nordisk shareholders. In the summer of 2024 ... Yesterday, the Danish Prime Minister, Mette Frederiksen, wrote a letter of condolence for the death of Pope Francis.